Pharmaceuticals

Imfinzi (Durvalumab) Market 2026–2035 advancing oncology immunotherapy

March 29, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Growth Is Projected For The Imfinzi (durvalumab) Market During The Forecast Period 2026–2030?

The imfinzi (durvalumab) market size has seen rapid expansion in recent years. It is projected to increase from $3.01 million in 2025 to $3.36 million in 2026, achieving a compound annual growth rate (CAGR) of 11.4%. The historical growth in this market can be attributed to the clinical success of immune checkpoint inhibitors, rising lung cancer prevalence, regulatory approvals in oncology, improved survival outcomes, and strong pharmaceutical investment.

The market size for imfinzi (durvalumab) is projected to undergo rapid expansion in the coming years. It is expected to reach $5.11 million by 2030, demonstrating a compound annual growth rate (CAGR) of 11.1%. This growth throughout the forecast period can be attributed to several factors including its expansion into new cancer indications, improved accessibility of immunotherapy, an increase in oncology clinical trials, rising healthcare spending in oncology, and the development of combination treatment protocols. Significant trends for the forecast period include the increasing adoption of PD-L1 inhibitors, the broadening application of immunotherapy in lung cancer, the proliferation of combination immuno-oncology regimens, a heightened focus on biomarker-driven therapies, and its more widespread use across multiple solid tumors.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19906&type=smp

Which Major Factors Are Driving The Expansion Of The Imfinzi (durvalumab) Market?

The increasing incidence of cancer is projected to stimulate the expansion of the Imfinzi (durvalumab) market. Cancer refers to a collection of illnesses typified by the unchecked proliferation and dissemination of atypical cells throughout the body, which can invade and devastate normal tissues. This rise in cancer cases is largely attributed to an aging populace, as susceptibility to cancer increases with age, and to lifestyle aspects such as smoking, poor dietary habits, and obesity, which foster higher rates of the disease. Durvalumab (Imfinzi) operates against cancer by blocking the PD-L1 protein, preventing malignant cells from avoiding detection by the immune system. As an illustration, the National Cancer Institute (NIH), a US-based government agency, reported in May 2024 that the U.S. had 18.1 million cancer survivors in 2022, a number projected to grow to 22.5 million by 2032. Thus, the heightened incidence of cancer is propelling the growth of the Imfinzi (durvalumab) market.

What Market Segments Are Evaluated Within The Imfinzi (durvalumab) Market?

The imfinzi (durvalumab) market covered in this report is segmented –

1) By Type: 2.4mL Injection, 10mL Injection

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By Application: Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Other Applications

What Industry Trends Are Redefining The Imfinzi (durvalumab) Market?

Leading firms within the Global Imfinzi (durvalumab) market are prioritizing the expansion of its approved indications, including its application in perioperative settings alongside chemotherapy, to secure a competitive edge. As an example, in January 2023, AstraZeneca plc, a biopharmaceutical company headquartered in the UK, disclosed that the combination of IMFINZI and chemotherapy significantly elevated the pathologic complete response rate, more than doubling it in early-stage resectable gastric and gastroesophageal junction cancers compared to chemotherapy by itself. This treatment involves two phases (before and after surgery) and offers a lasting benefit in immune activation. This expansion into treating gastrointestinal cancers highlights AstraZeneca’s strategic approach to enhance its clinical presence and foster sustained product adoption over time. Nevertheless, this approach also introduces regulatory challenges, given that more intricate treatment protocols necessitate further clinical trial data and validation from a health economic perspective.

Who Are The Top Market Participants Influencing The Imfinzi (durvalumab) Market?

Major companies operating in the imfinzi (durvalumab) market are AstraZeneca PLC.

Read the full imfinzi (durvalumab) market report here:

https://www.thebusinessresearchcompany.com/report/imfinzi-durvalumab-global-market-report

Which Region Currently Holds The Largest Share Of The Imfinzi (durvalumab) Market?

North America was the largest region in the imfinzi (durvalumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the imfinzi (durvalumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Imfinzi (durvalumab) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19906&type=smp

Browse Through More Reports Similar to the Global Imfinzi (durvalumab) Market 2026, By The Business Research Company

Adalimumab Infliximab And Etanercept Biosimilars Market 2026

https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilars-market

Bevacizumab Biosimilars Market Report 2026

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Vertical Market Software Market Report 2026

https://www.thebusinessresearchcompany.com/report/vertical-market-software-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795